

3AG

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 February 2005 (24.02.2005)

PCT

(10) International Publication Number
WO 2005/016867 A2

(51) International Patent Classification⁷: C07C 233/55,
C07D 209/18, 317/60, 217/14, C07C 237/22, C07D
215/36, C07C 235/38, C07D 333/60, C07C 235/24, A61K
31/196, 31/33

Frontiers Science Park South, Third Avenue, Harlow
Essex CM19 5AW (GB). SMITH, Ian, Edward, David
[GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Steven-
age Hertfordshire SG1 2NY (GB).

(21) International Application Number:
PCT/GB2004/003516

(74) Agent: THORNLEY, Rachel, Mary; GlaxoSmithKline,
Corporate Intellectual Property (CN925.1), 980 Great West
Road, Brentford Middlesex TW8 9GS (GB).

(22) International Filing Date: 13 August 2004 (13.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0319126.9 14 August 2003 (14.08.2003) GB

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, PO Box 7929, Philadelphia,
Pennsylvania 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CAMPBELL,
Mathew [GB/GB]; GlaxoSmithKline, Gunnels Wood
Road, Stevenage Hertfordshire SG1 2NY (GB). HAT-
LEY, Richard, Jonathan [GB/GB]; GlaxoSmithKline,
Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY
(GB). HEER, Jag, Paul [GB/GB]; GlaxoSmithKline,
New Frontiers Science Park South, Third Avenue, Harlow
Essex CM19 5AW (GB). MASON, Andrew, McMur-
trie [GB/GB]; GlaxoSmithKline, Gunnels Wood Road,
Stevenage Hertfordshire SG1 2NY (GB). PINTO, Ivan,
Leo [GB/GB]; GlaxoSmithKline, Gunnels Wood Road,
Stevenage Hertfordshire SG1 2NY (GB). RAHMAN,
Shahzad, Sharooq [GB/GB]; GlaxoSmithKline, New

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: CHEMICAL COMPOUNDS



(I)

(57) Abstract: Therapeutically active anthranilic acid derivatives of Formula (I) wherein R₁, R₂ and Z are as defined in the speci-
fication, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compounds and the use
of the compounds in therapy, particularly in the treatment of diseases in which under-activation of the HM74A receptor contributes
to the disease or in which activation of the receptor will be beneficial, are disclosed.

WO 2005/016867 A2

CHEMICAL COMPOUNDS

5 The present invention relates to therapeutically active compounds which are anthranilic acid derivatives, processes for the manufacture of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, particularly in the treatment of diseases in which under-activation of the HM74A receptor contributes to the disease or in which activation of the receptor will be beneficial.

10 Dyslipidaemia is a general term used to describe individuals with aberrant lipoprotein profiles. Clinically, the main classes of compounds used for the treatment of patients with dyslipidaemia, and therefore at risk of cardiovascular disease are the statins, fibrates, bile-acid binding resins and nicotinic acid. Nicotinic acid (Niacin, a B vitamin)
15 has been used clinically for over 40 years in patients with various forms of dyslipidaemia. The primary mode of action of nicotinic acid is via inhibition of hormone-sensitive triglyceride lipase (HSL), which results in a lowering of plasma non-esterified fatty acids (NEFA) which in turn alters hepatic fat metabolism to reduce the output of LDL and VLDL (low and very low density lipoprotein). Reduced VLDL levels are thought to lower cholesterol ester transfer protein (CETP) activity to result in
20 increased HDL (high density lipoprotein) levels which may be the cause of the observed cardiovascular benefits. Thus, nicotinic acid produces a very desirable alteration in lipoprotein profiles; reducing levels of VLDL and LDL whilst increasing HDL. Nicotinic acid has also been demonstrated to have disease modifying benefits, reducing the progression and increasing the regression of atherosclerotic lesions and
25 reducing the number of cardiovascular events in several trials.

The observed inhibition of HSL by nicotinic acid treatment is mediated by a decrease in cellular cyclic adenosine monophosphate (cAMP) caused by the G-protein-mediated inhibition of adenylyl cyclase. Recently, the G-protein coupled receptors HM74 and
30 HM74A have been identified as receptors for nicotinic acid (PCT patent application WO02/84298; Wise et. al. J Biol Chem. 2003 **278** (11) 9869-9874). The DNA sequence of human HM74A may be found in Genbank; accession number AY148884. Two other papers support this discovery, (Tunaru et. al. Nature Medicine 2003 (3) 352-255 and Soga et. al. Biochem Biophys Res Commun. 2003 **303** (1) 364-369),
35 however the nomenclature differs slightly. In the Tunaru paper what they term human HM74 is in fact HM74A and in the Soga paper HM74b is identical to HM74A. Cells transfected to express HM74A and/or HM74 gain the ability to elicit G_i G-protein mediated responses following exposure to nicotinic acid. In mice lacking the homologue of HM74A (m-PUMA-G) nicotinic acid fails to reduce plasma NEFA levels.
40

Certain anthranilic acid derivatives have been synthesised and disclosed in the prior art. For example, US patent No. 5,075,313 and Yu, Melvin J. et. al. J. Med. Chem.

1992, vol. 35, 2534-2542 both relate to 3-aryl-4(3H)quinazolinone CCK antagonists useful in treating CNS and gastrointestinal disorders and discloses certain anthranilic acid derivatives as intermediates in their synthesis.

5 We now present a group of anthranilic acid derivatives which are selective agonists of the nicotinic acid receptor HM74A and are thus of benefit in the treatment, prophylaxis and suppression of diseases in which under-activation of this receptor either contributes to the disease or in which activation of the receptor will be beneficial.


10 Summary of the Invention

The present invention provides therapeutically active anthranilic acid derivatives and the use of these derivatives in therapy, particularly in the treatment of diseases in which under-activation of the HM74A receptor contributes to the disease or in which
15 activation of the receptor will be beneficial, in particular diseases of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia. As such, the compounds may also find favour as therapeutics for coronary artery disease,
20 thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity. The compounds may also be of use in the treatment of inflammatory diseases or conditions, as set out further below.

25 Intermediates, formulations, methods and processes described herein form further aspects of the invention.

30 Detailed Description of the Invention

According to one aspect of this invention, we provide a compound of Formula (I)



and salts, solvates and physiologically functional derivatives thereof, wherein:

R¹ represents hydrogen, halogen or C₁-C₃alkyl;

R^2 represents a 9 or 10-member saturated, partially saturated or unsaturated bi-cyclic ring system optionally including from 1 to 3 heteroatoms independently selected from S, O and N;

5 Z represents a linker unit selected from: $-(CH_2)_n-$; $-CH=CH-(CH_2)_m-$; $-(CH_2)_pNHC(O)-$; $-(CH_2)_pNHC(O)NH-$; $-(CH_2)_pNHC(O)O-$; $-(CH_2)_pSO_2NR^3-$; $-(CH_2)_pNR^3SO_2-$; $-(CH_2)_pO-$ and $-O-$;

n represents an integer selected from 2, 3 and 4;

10

m represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2; and

15 R^3 represents hydrogen or C_1 - C_4 alkyl;

with the proviso that when R^1 is H, Z is $-(CH_2)_n-$ and $n = 2$ or 3 , R^2 is other than indol-3-yl.

20 The compounds are of use in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial, in particular diseases of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia. As such, the compounds may also find
25 favour as therapeutics for coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity.

30

In certain embodiments, R^1 groups are hydrogen, fluorine or methyl (e.g. hydrogen).

In certain particular embodiments, Z represents $-(CH_2)_n-$, $-(CH_2)_pO-$ or $-CH=CH-(CH_2)_m-$.

35

In particular embodiments of the invention, n represents 2 or 3 (e.g. 2).

In certain compounds of the invention, m represents 0 or 1.


40

In particular embodiments, p represents 1.

R^3 represents hydrogen or methyl in certain embodiments of the invention.


5 R^2 may represent a biaryl, hetero-biaryl, fused aryl-cycloalkyl, fused heteroaryl-cycloalkyl, fused aryl-heterocycle or fused heteroaryl-heterocyclic ring system, as herein defined. In certain embodiments in which R^2 includes heteroatoms, 1 to 3 heteroatoms are present. The R^2 ring system may be joined to the Z linker unit via either a ring carbon atom or via a heteroatom, where present.

10 In certain compounds of the present invention in which the R^2 unit is a 10-member ring system, this may be naphthyl or may have either 1 or 2 heteroatoms. Where 2 heteroatoms are present, particular embodiments will have both in the same ring of the fused system. In particular embodiments, the heteroatoms in a 10-member ring system are nitrogen atoms. In certain embodiments, a 10-member R^2 group is selected from the group consisting of:




15 Where the R^2 unit is a 10-member ring system, this may be unsubstituted. In certain embodiments in which R^2 is a substituted 10-member ring system, the substituents are selected from C_1 - C_2 alkyl, (e.g. methyl), $-C(O)Me$, $=O$ and C_1 - C_3 alkoxy (e.g. methoxy).

20 Where the R^2 unit is a 9-member ring system, this may be fused aryl-cycloalkyl, for example:



optionally including up to 3 heteroatoms selected from S, O or N, or may be a 9-member fused aryl or heteroaryl system, optionally including up to 3 heteroatoms selected from S, O or N. In particular embodiments in which the R^2 unit is a 9-member

- 5 ring system containing heteroatoms, these may be situated in the 5-member ring of the fused system. In particulate embodiments where more than one heteroatom is present, they are both the same such as, for example, a benzimidazole derivative, although heterogeneous heteroaryl systems are also included. In certain embodiments, a 9-member R^2 group is selected from the group consisting of:



wherein R^4 represents hydrogen, methyl, CO_2H or CO_2Me .

- 10 Where the R^2 unit is a 9-member ring system, including those depicted above, this may be unsubstituted. In certain embodiments in which R^2 is a substituted 9-member ring system, the one or more substituents are selected from C_1 - C_2 alkyl (e.g. methyl); $-\text{C}(\text{O})\text{Me}$; $=\text{O}$; C_1 - C_3 alkoxy (e.g. methoxy); CO_2H ; and CO_2Me .
- 15 In certain embodiments:
 where the linker unit Z is $-(\text{CH}_2)_n-$, n is 2 or 3, more particularly 2;
 where Z is $-\text{CH}=\text{CH}-(\text{CH}_2)_m-$, m is 0 or 1, more particularly 0 (in which case Z is $-\text{CH}=\text{CH}-$); and
 where Z is $-(\text{CH}_2)_p\text{O}-$; $-(\text{CH}_2)_p\text{NHC}(\text{O})-$; $-(\text{CH}_2)_p\text{NHC}(\text{O})\text{NH}-$; $-(\text{CH}_2)_p\text{NHC}(\text{O})\text{O}-$; $-(\text{CH}_2)_p\text{SO}_2\text{NR}^3-$ or $-(\text{CH}_2)_p\text{NR}^3\text{SO}_2-$, p is 1.
- 20

It is to be understood that the present invention includes any combination of particular embodiments and covers all combinations of particular substituents described hereinabove.

- 25 Throughout the present specification and the accompanying claims the words "comprise" and "include" and variations such as "comprises", "comprising", "includes" and "including" are to be interpreted inclusively. That is, these words are intended to

convey the possible inclusion of other elements or integers not specifically recited, where the context allows.

5 As used herein, the terms "halogen" or "halo" refer to fluorine, chlorine, bromine and iodine.


As used herein, the term "alkyl" (when used as a group or as part of a group) refers to a straight or branched hydrocarbon chain containing the specified number of carbon atoms. For example, C₁-C₃alkyl means a straight or branched hydrocarbon chain
10 containing at least 1 and at most 3 carbon atoms. Examples of alkyl as used herein include, but are not limited to; methyl (Me), ethyl (Et), n-propyl, i-propyl.

As used herein, the term "alkoxy" (when used as a group or as part of a group) refers to an alkyl ether radical, wherein the term "alkyl" is defined above. Examples of alkoxy
15 as used herein include, but are not limited to; methoxy, ethoxy, n-propoxy, i-propoxy and the like.

As used herein, the term "biaryl" (when used as a group or as part of a group) refers to a group containing two aromatic rings which have two atoms in common. Examples of
20 fused biaryl as used herein include, but are not limited to naphthyl and indyl. Said biaryl groups may be optionally substituted with one or more groups selected from C₁-C₃alkyl, C₁-C₃alkoxy, -C(O)Me, CO₂H, CO₂Me and =O.

As used herein, the term "hetero-biaryl" (when used as a group or as part of a group) refers to a biaryl group which contains one or more nitrogen, sulphur, or oxygen
25 heteroatoms. Examples of hetero-biaryl as used herein include, but are not limited to; quinoline, isoquinoline, quinoxaline, benzimidazole, indolizine, indole and benzothiophene groups. Said hetero-biaryl groups may be optionally substituted with one or more groups selected from C₁-C₃alkyl, C₁-C₃alkoxy, -C(O)Me, CO₂H, CO₂Me
30 and =O.

As used herein, the term "fused aryl-cycloalkyl" (when used as a group or as part of a group) refers to a group containing one aromatic ring and one alicyclic ring which have
35 two atoms in common. Examples of fused aryl-cycloalkyl as used herein include, but are not limited to;



Said fused aryl-cycloalkyl groups may be optionally substituted with one or more groups selected from C₁-C₃alkyl, C₁-C₃alkoxy, -C(O)Me, CO₂H, CO₂Me and =O.

5 As used herein, the term "fused heteroaryl-cycloalkyl" (when used as a group or as part of a group) refers to a fused aryl-cycloalkyl group, the aryl ring of which contains one or more nitrogen, sulphur, or oxygen heteroatoms. Said fused heteroaryl-cycloalkyl groups may be optionally substituted with one or more groups selected from C₁-C₃alkyl, C₁-C₃alkoxy, -C(O)Me, CO₂H, CO₂Me and =O.

10 As used herein, the term "fused aryl-heterocycle" (when used as a group or as part of a group) refers to a fused aryl-cycloalkyl group, the alicyclic ring of which contains one or more nitrogen, sulphur, or oxygen heteroatoms. Examples of fused aryl-heterocycle as used herein include, but are not limited to; benzodioxolane, indoline. Said fused aryl-heterocycle groups may be optionally substituted with one or more groups
15 selected from C₁-C₃alkyl, C₁-C₃alkoxy, -C(O)Me, CO₂H, CO₂Me and =O.

As used herein, the term "fused heteroaryl-heterocyclic" (when used as a group or as part of a group) refers to a fused aryl-cycloalkyl group, which contains one or more nitrogen, sulphur, or oxygen heteroatoms either present as an atom shared between
20 the two rings, or one or more heteroatoms being present in each ring. Said fused heteroaryl-heterocyclic groups may be optionally substituted with one or more groups selected from C₁-C₃alkyl, C₁-C₃alkoxy, -C(O)Me, CO₂H, CO₂Me and =O.

As used herein, the term "physiologically functional derivative" refers to any
25 pharmaceutically acceptable derivative of a compound of the present invention, for example an ester or an amide thereof, and includes any pharmaceutically acceptable salt, ester, or salt of such ester of a compound of formula (I) which, upon administration to a mammal, such as a human, is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof. It will
30 be appreciated by those skilled in the art that the compounds of formula (I) may be modified to provide physiologically functional derivatives thereof at any of the functional groups in the compounds, and that the compounds of formula (I) may be so modified at more than one position.

35 As used herein, the term "pharmaceutically acceptable" used in relation to an ingredient (active ingredient or excipient) which may be included in a pharmaceutical formulation for administration to a patient, refers to that ingredient being acceptable in the sense of being compatible with any other ingredients present in the pharmaceutical formulation and not being deleterious to the recipient thereof.

40 As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I), a salt thereof or a

physiologically functional derivative thereof) and a solvent. Such solvents for the purposes of the present invention may not interfere with the biological activity of the solute. Examples of suitable solvents include water, methanol, ethanol and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid. Most preferably the solvent used is water, in which case the solvate may be referred to as a hydrate of the solute in question.

It will be appreciated that, for pharmaceutical use, the "salt or solvate" referred to above will be a pharmaceutically acceptable salt or solvate. However, other salts or solvates may find use, for example, in the preparation of a compound of formula (I) or in the preparation of a pharmaceutically acceptable salt or solvate thereof.

Pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse, *J. Pharm. Sci.*, 1977, 66, 1-19. Suitable pharmaceutically acceptable salts include acid addition salts formed from the addition of inorganic acids or organic acids, preferably inorganic acids. Examples of suitable acid addition salts include hydrochlorides, hydrobromides, sulphates and acetates. Further representative examples of pharmaceutically acceptable salts include those formed from maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bismethylenesalicylic, methanesulfonic, ethanedisulfonic, propionic, tartaric, salicylic, citric, gluconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, cyclohexylsulfamic, phosphoric and nitric acids. Suitable pharmaceutically acceptable salts also include alkali metal salts formed from the addition of alkali metal bases such as alkali metal hydroxides. An example of a suitable alkali metal salt is a sodium salt.

Compounds of the present invention are of potential therapeutic benefit in the treatment and amelioration of the symptoms of many diseases of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia. As such, the compounds may also find favour as therapeutics for coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity. The use of a compound of Formula (I) in the treatment of one or more of these diseases is a further aspect of the present invention.

Furthermore, it is also believed that the HM74 and HM74A receptors are involved in inflammation. Inflammation represents a group of vascular, cellular and neurological responses to trauma. Inflammation can be characterised as the movement of inflammatory cells such as monocytes, neutrophils and granulocytes into the tissues.

This is usually associated with reduced endothelial barrier function and oedema into the tissues. Inflammation with regards to disease typically is referred to as chronic inflammation and can last up to a lifetime. Such chronic inflammation may manifest itself through disease symptoms. The aim of anti-inflammatory therapy is therefore to reduce this chronic inflammation and allow for the physiological process of healing and tissue repair to progress.

Thus, a further aspect of the present invention resides in the use of a compound of Formula (I) or a salt, solvate or physiologically functional derivative thereof as defined above in the treatment of inflammatory diseases or conditions of the joint, particularly arthritis (e.g. rheumatoid arthritis, osteoarthritis, prosthetic joint failure), or the gastrointestinal tract (e.g. ulcerative colitis, Crohn's disease, and other inflammatory bowel and gastrointestinal diseases, gastritis and mucosal inflammation resulting from infection, the enteropathy provoked by non-steroidal anti-inflammatory drugs), of the lung (e.g. adult respiratory distress syndrome, asthma, cystic fibrosis, or chronic obstructive pulmonary disease), of the heart (e.g. myocarditis), of nervous tissue (e.g. multiple sclerosis), of the pancreas, (e.g. inflammation associated with diabetes melitus and complications thereof), of the kidney (e.g. glomerulonephritis), of the skin (e.g. dermatitis, psoriasis, eczema, urticaria, burn injury), of the eye (e.g. glaucoma) as well as of transplanted organs (e.g. rejection) and multi-organ diseases (e.g. systemic lupus erythematosus, sepsis) and inflammatory sequelae of viral or bacterial infections and inflammatory conditions associated with atherosclerosis and following hypoxic or ischaemic insults (with or without reperfusion), for example in the brain or in ischaemic heart disease.

In particular, the compounds of Formula (I) are useful in the treatment and prevention of inflammation, and cardiovascular diseases or conditions including atherosclerosis, arteriosclerosis, hypertriglyceridemia, and mixed dyslipidaemia.

Thus, there is also provided the use of a compound of Formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, in the manufacture of a medicament for the treatment of disorders of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia. The compounds are also provided for use in the treatment of coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity.

Nicotinic acid has a significant side effect profile, possibly because it is dosed at high level (gram quantities daily). The most common side effect is an intense cutaneous flushing. The compounds of the present invention preferably exhibit reduced side effects compared to nicotinic acid. HM74A has been identified as a high affinity receptor for nicotinic acid whilst HM74 is a lower affinity receptor. The compounds of the present invention are selective for HM74A by which is meant that they show greater affinity for HM74A than for HM74.

The potential for compounds of formula (I) to activate HM74A may be demonstrated, for example, using the following enzyme and in vitro whole cell assays:

In-vitro testing

For transient transfections, HEK293T cells (HEK293 cells stably expressing the SV40 large T-antigen) were maintained in DMEM containing 10% foetal calf serum and 2mM glutamine. Cells were seeded in 90mm culture dishes and grown to 60-80% confluence (18-24h) prior to transfection. Human HM74A (GenBank™ accession number AY148884) was subcloned in to a mammalian expression vector (pcDNA3; Invitrogen) and transfected using Lipofectamine reagent. For transfection, 9µg of DNA was mixed with 30µl Lipofectamine in 0.6ml of Opti-MEM (Life Technologies Inc.) and was incubated at room temperature for 30min prior to the addition of 1.6ml of Opti-MEM. Cells were exposed to the Lipofectamine/DNA mixture for 5h and 6ml of 20% (v/v) foetal calf serum in DMEM was then added. Cells were harvested 48h after transfection. Pertussis toxin treatment was carried out by supplementation into media at 50ngml⁻¹ for 16h. All transient transfection studies involved co-transfection of receptor together with the G₁₀ G protein, G_{o1}α.

For generation of stable cell lines the above method was used to transfect CHO-K1 cells seeded in six well dishes grown to 30% confluence. These cells were maintained in DMEM F-12 HAM media containing 10% foetal calf serum and 2mM glutamine. 48h post-transfection the media was supplemented with 400µg/ml Geneticin (G418, Gibco) for selection of antibiotic resistant cells. Clonal CHO-K1 cell lines stably expressing HM74A were confirmed by [³⁵S]-GTPγS binding measurements, following the addition of nicotinic acid.

P2 membrane preparation - Plasma membrane-containing P2 particulate fractions were prepared from cell pastes frozen at -80°C after harvest. All procedures were carried out at 4°C. Cell pellets were resuspended in 1 ml of 10mM Tris-HCl and 0.1mM EDTA, pH 7.5 (buffer A) and by homogenisation for 20s with a Ultra Turrax followed by passage (5 times) through a 25-gauge needle. Cell lysates were centrifuged at 1,000g for 10 min in a microcentrifuge to pellet the nuclei and unbroken cells and P2 particulate fractions were recovered by microcentrifugation at 16,000g for

30min. P2 particulate fractions were resuspended in buffer A and stored at -80°C until required.

[^{35}S]-GTP γS binding - Assays were performed at room temperature either in 96-well format as described previously (Wieland, T. and Jakobs, K.H. (1994) *Methods Enzymol.* **237**, 3-13) or in an adapted protocol carried out in 384-well format.

96-well format: Briefly, membranes (10 μg per point) were diluted to 0.083 mg/ml in assay buffer (20 mM HEPES, 100 mM NaCl, 10 mM MgCl_2 , pH7.4) supplemented with saponin (10 mg/l) and pre-incubated with 10 μM GDP. Various concentrations of nicotinic acid or related molecules were added, followed by [^{35}S]-GTP γS (1170 Ci/mmol, Amersham) at 0.3 nM (total vol. of 100 μl) and binding was allowed to proceed at room temperature for 30 min. Non-specific binding was determined by the inclusion of 0.6 mM GTP. Wheatgerm agglutinin SPA beads (Amersham) (0.5 mg) in 25 μl assay buffer were added and the whole was incubated at room temperature for 30 min with agitation. Plates were centrifuged at 1500 g for 5 min and bound [^{35}S]-GTP γS was determined by scintillation counting on a Wallac 1450 microbeta Trilux scintillation counter.

384-well format: Briefly, the dilution of standard or test compounds were prepared and added to a 384-well plate in a volume of 10 μl . Membranes (HM74A or HM74) were diluted in assay buffer (20mM HEPES, 100mM NaCl, 10mM MgCl_2 , pH7.4) supplemented with saponin (60 $\mu\text{g}/\text{ml}$), Leadseeker WGA beads (Amersham; 250 $\mu\text{g}/\text{well}$) and 10 μM GDP, so that the 20 μl volume added to each well contains 5 μg of membranes. [^{35}S]-GTP γS (1170 Ci/mmol, Amersham) was diluted (1:1500) in assay buffer and 20 μl added to each well. Following the addition of the radioligand, the plates were sealed, pulse spun and incubated for 4hours at room temperature. At the end of the incubation period the plates were read on a Leadseeker machine (VIEWLUX PLUS; Perkin-Elmer) to determine the levels of specific binding.

Compounds according to Formula (I) have been synthesised (see synthetic examples below) and tested in one or more of the assays discussed above. The compounds have an EC_{50} of 5.0 or greater and an efficacy of 30% or greater.

In-vivo testing

HM74A agonists are tested in male Spague-Dawley rats (200-250grammes) which have been fasted for at least 12 hours prior to the study. The compounds are dosed intravenously (5ml/kg) or by oral gavage (10ml/kg). Blood samples (0.3ml tail vein bleed) are taken pre-dose and at three times post-dose (times ranging from 15minutes to 8 hours post-dose). Each blood sample is transferred to a heparin tube (Becton

Dickinson Microtainer, PST LH) and centrifuged (10,000 g for 5 minutes) to produce a plasma sample. The plasma samples are assayed for levels of non-esterified fatty acids (NEFA) using a commercially available kit (Randox). Inhibition of plasma NEFA levels, relative to pre-dose levels, is used as a surrogate for HM74A agonist activity.


In order to determine whether compounds of the invention exhibit the flushing response associated with nicotinic acid, they are dosed to anaesthetised guinea-pigs. Nicotinic acid is used as positive control. Male Dunkin Hartley guinea pigs (300-800g) are fasted for 12 hours prior to being anaesthetised with a mixture of Ketamine hydrochloride (Vetalar, 40mg/kg i.m.), Xylazine (Rompun, 8mg/kg i.m.) and sodium pentobarbitone (Sagatal, 30mg/kg i.p.). Following anaesthesia a tracheostomy is performed and the animals are mechanically ventilated with room air (10-12mL/kg, 60 breaths/min). A jugular vein, and a carotid artery, are cannulated for intravenous administration of test compound and collection of blood respectively. An infra-red temperature probe (Extech Instruments) is placed 3-5mm from the tip of the left ear. Temperature measurements are recorded every minute from 5 minutes prior to test compound or nicotinic acid and up to 40 minutes post-administration of test compound or nicotinic acid. Data is automatically collected on a Psion computer before being transferred for data analysis within an Excel spreadsheet. Prior to, and at frequent time points after compound administration, blood samples (0.3ml) are taken via the carotid arterial cannula and transferred to Microtainer (BD) tubes containing lithium heparin. The samples are mixed thoroughly on a blood roller and then stored on ice prior to centrifugation at 1200g for 5 minutes.

As indicated above, compounds of Formula (I) are useful in human or veterinary medicine, in particular as activators of HM74A, in the management of dyslipidaemia and hyperlipoproteinaemia.

Thus, there is provided as a further aspect of the present invention a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, for use in human or veterinary medicine, particularly in the treatment of disorders of lipid metabolism including dyslipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, hypertriglyceridaemia, coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity.

It will be appreciated that references herein to treatment extend to prophylaxis, prevention of recurrence and suppression of symptoms as well as the treatment of established conditions.

According to another aspect of the invention, there is provided the use of a compound of formula (Ia)



5 or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, wherein

R^1 represents hydrogen, halogen or C_1 - C_3 alkyl;

10 R^2 represents a 9 or 10-member saturated, partially saturated or unsaturated bi-cyclic ring system optionally including from 1 to 3 heteroatoms independently selected from S, O and N;

15 Z represents a linker unit selected from: $-(CH_2)_n-$; $-CH=CH-(CH_2)_m-$; $-(CH_2)_pNHC(O)-$; $-(CH_2)_pNHC(O)NH-$; $-(CH_2)_pNHC(O)O-$; $-(CH_2)_pSO_2NR^3-$; $-(CH_2)_pNR^3SO_2-$; $-(CH_2)_pO-$; and $-O-$;

n represents an integer selected from 2, 3 and 4;

20 m represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2; and

R^3 represents hydrogen or C_1 - C_4 alkyl,

25 in the manufacture of a medicament for the treatment of disorders of lipid metabolism including dislipidaemia or hyperlipoproteinaemia. In particular, the use is provided of a compound of Formula (Ia) in the manufacture of a medicament for the treatment of diabetic dyslipidaemia, mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and
30 hypertriglyceridaemia, coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity.

35

In certain embodiments of Formula (Ia), R^1 groups are hydrogen, fluorine or methyl (e.g. hydrogen).

5 In certain particular embodiments, Z represents $-(CH_2)_n-$, $-(CH_2)_pO-$ or $-CH=CH-(CH_2)_m-$.

In particular preferred embodiments of the invention, n represents 2 or 3 (e.g. 2).


10 In certain compounds of the invention, m represents 0 or 1.

In particular embodiments, p represents 1.

R^3 represents hydrogen or methyl in certain embodiments of the invention.


15 R^2 may represent a biaryl, hetero-biaryl, fused aryl-cycloalkyl, fused heteroaryl-cycloalkyl, fused aryl-heterocycle or fused heteroaryl-heterocyclic ring system, as herein defined. In certain embodiments in which R^2 includes heteroatoms, 1 to 3 heteroatoms are present. The R^2 ring system may be joined to the Z linker unit via either a ring carbon atom or via a heteroatom, where present.

20 In certain compounds of the present invention in which the R^2 unit is a 10-member ring system, this may be naphthyl or may have either 1 or 2 heteroatoms. Where 2 heteroatoms are present, particular embodiments will have both in the same ring of the fused system. In particular embodiments, the heteroatoms in a 10-member ring system are nitrogen atoms. In certain embodiments, a 10-member R^2 group is selected from the group consisting of:




Where the R^2 unit is a 10-member ring system, this may be unsubstituted. In certain embodiments in which R^2 is a substituted 10-member ring system, the substituents are selected from C_1 - C_2 alkyl, (e.g. methyl), $-C(O)Me$, $=O$ and C_1 - C_3 alkoxy (e.g. methoxy).

- 5 Where the R^2 unit is a 9-member ring system, this may be fused aryl-cycloalkyl, for example:



- 10 optionally including up to 3 heteroatoms selected from S, O or N, or may be a 9-member fused aryl or heteroaryl system, optionally including up to 3 heteroatoms selected from S, O or N. In particular embodiments in which the R^2 unit is a 9-member ring system containing heteroatoms, these may be situated in the 5-member ring of the fused system. In particulate embodiments where more than one heteroatom is present, they are both the same such as, for example, a benzimidazole derivative, although heterogeneous heteroaryl systems are also included. In certain
- 15 embodiments, a 9-member R^2 group is selected from the group consisting of:



wherein R^4 represents hydrogen, methyl, CO_2H or CO_2Me .

- 20 Where the R^2 unit is a 9-member ring system, including those depicted above, this may be unsubstituted. In certain embodiments in which R^2 is a substituted 9-member ring system, the one or more substituents are selected from C_1 - C_2 alkyl (e.g. methyl); $-C(O)Me$; $=O$; C_1 - C_3 alkoxy (e.g. methoxy); CO_2H ; and CO_2Me .

In certain embodiments:

where the linker unit Z is $-(CH_2)_n-$, n is 2 or 3, more particularly 2;

where Z is $-CH=CH-(CH_2)_m-$, m is 0 or 1, more particularly 0 (in which case Z is $-CH=CH-$); and

where Z is $-(CH_2)_pO-$, $-(CH_2)_pNHC(O)-$, $-(CH_2)_pNHC(O)NH-$, $-(CH_2)_pNHC(O)O-$, $-(CH_2)_pSO_2NR^3-$ or $-(CH_2)_pNR^3SO_2-$, p is 1.

It is to be understood that this aspect of the present invention includes, with respect to the use of compounds of Formula (I) or of Formula (Ia) in the manufacture of a medicament, any combination of particular embodiments and covers all combinations of particular substituents of compounds of Formula (I) or of Formula (Ia) described hereinabove.

Additionally, the present invention provides the use of a compound of formula (Ia) or a physiologically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of inflammatory diseases or conditions of the joint, particularly arthritis (e.g. rheumatoid arthritis, osteoarthritis, prosthetic joint failure), or of the gastrointestinal tract (e.g. ulcerative colitis, Crohn's disease, and other inflammatory bowel and gastrointestinal diseases, gastritis and mucosal inflammation resulting from infection, the enteropathy provoked by non-steroidal anti-inflammatory drugs), of the lung (e.g. adult respiratory distress syndrome, asthma, cystic fibrosis, or chronic obstructive pulmonary disease), of the heart (e.g. myocarditis), of nervous tissue (e.g. multiple sclerosis), of the pancreas, (e.g. inflammation associated with diabetes mellitus and complications thereof, of the kidney (e.g. glomerulonephritis), of the skin (e.g. dermatitis, psoriasis, eczema, urticaria, burn injury), of the eye (e.g. glaucoma) as well as of transplanted organs (e.g. rejection) and multi-organ diseases (e.g. systemic lupus erythematosus, sepsis) and inflammatory sequelae of viral or bacterial infections and inflammatory conditions associated with atherosclerosis and following hypoxic or ischaemic insults (with or without reperfusion), for example in the brain or in ischaemic heart disease.

In a further or alternative aspect there is provided a method for the treatment of a human or animal subject with a condition where under-activation of the HM74A receptor contributes to the condition or where activation of the receptor will be beneficial, which method comprises administering to said human or animal subject an effective amount of a compound of formula (Ia) or a physiologically acceptable salt or solvate thereof.

Again, it is to be understood that this aspect of the present invention includes, with respect to the use of compounds of Formula (I) or of Formula (Ia) in the manufacture of a medicament, any combination of particular embodiments and covers all

combinations of particular substituents of compounds of Formula (I) or of Formula (Ia) described hereinabove.

5 More particularly, the present invention provides a method for the treatment of disorders of lipid metabolism including dyslipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity, which method comprises administering to
10 said human or animal subject an effective amount of a compound of formula (Ia) or a physiologically acceptable salt or solvate thereof. As such, these compounds may also find favour in methods for the treatment of coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, which methods comprise administering to said human or animal subject an effective amount of a
15 compound of formula (Ia).

The amount of a HM74A modulator which is required to achieve the desired biological effect will, of course, depend on a number of factors, for example, the mode of administration and the precise clinical condition of the recipient. In general, the daily
20 dose will be in the range of 0.1mg - 1g/kg, typically 0.1 - 100mg/kg. An intravenous dose may, for example, be in the range of 0.01mg to 0.1g/kg, typically 0.01mg to 10mg/kg, which may conveniently be administered as an infusion of from 0.1µg to 1mg, per minute. Infusion fluids suitable for this purpose may contain, for example, from 0.01µg to 0.1mg, per millilitre. Unit doses may contain, for example, from 0.01µg
25 to 1g of a HM74A modulator. Thus ampoules for injection may contain, for example, from 0.01µg to 0.1g and orally administrable unit dose formulations, such as tablets or capsules, may contain, for example, from 0.1mg to 1g. No toxicological effects are indicated/expected when a compound of the invention is administered in the above mentioned dosage range.

30 A compound of the present invention may be employed as the compound *per se* in the treatment of a disease where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial, but is preferably presented with an acceptable carrier in the form of a pharmaceutical formulation. The
35 carrier must, of course, be acceptable in the sense of being compatible with the other ingredients of the formulation and must not be deleterious to the recipient. The carrier may be a solid or a liquid, or both, and is preferably formulated with the HM74A modulator as a unit-dose formulation, for example, a tablet, which may contain from 0.05% to 95% by weight of the HM74A modulator.

40

The formulations include those suitable for oral, rectal, topical, buccal (e.g. sub-lingual) and parenteral (e.g. subcutaneous, intramuscular, intradermal or intravenous) administration.

- 5 There is also provided according to the invention a process for preparation of such a pharmaceutical composition which comprises mixing the ingredients.

Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges or tablets, each containing a predetermined amount of
10 a HM74A modulator; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. In general, the formulations are prepared by uniformly and intimately admixing the active HM74A modulator with a liquid or finely divided solid carrier, or both, and then, if
15 necessary, shaping the product. For example, a tablet may be prepared by compressing or moulding a powder or granules of the HM74A modulator optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent and/or surface active/dispersing agent(s). Moulded tablets may be made by moulding, in a
20 suitable machine, the powdered compound moistened with an inert liquid diluent.

Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinyl pyrrolidone; fillers, for example, lactose, microcrystalline cellulose,
25 sugar, maize- starch, calcium phosphate or sorbitol; lubricants, for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica; disintegrants, for example, potato starch, croscarmellose sodium or sodium starch glycollate; or wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for
30 example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxymethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or
35 hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; or preservatives, for example, methyl or propyl p-hydroxybenzoates or sorbic acid. The preparations may also contain buffer salts, flavouring, colouring and/or sweetening
40 agents (e.g. mannitol) as appropriate.

Formulations suitable for buccal (sub-lingual) administration include lozenges comprising a HM74A modulator in a flavoured base, usually sucrose and acacia or tragacanth, and pastilles comprising the HM74A modulator in an inert base such as gelatin and glycerin or sucrose and acacia.

5

Formulations of the present invention suitable for parenteral administration conveniently comprise sterile aqueous preparations of an HM74A modulator, preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although administration may also be effected by means of subcutaneous, intramuscular, or intradermal injection. Such preparations may conveniently be prepared by admixing the HM74A modulator with water and rendering the resulting solution sterile and isotonic with the blood. Injectable compositions according to the invention will generally contain from 0.1 to 5% w/w of the HM74A modulator.

15

Thus, formulations of the present invention suitable for parenteral administration comprising a compound according to the invention may be formulated for parenteral administration by bolus injection or continuous infusion and may be presented in unit dose form, for instance as ampoules, vials, small volume infusions or pre-filled syringes, or in multi-dose containers with an added preservative. The compositions may take such forms as solutions, suspensions, or emulsions in aqueous or non-aqueous vehicles, and may contain formulatory agents such as anti-oxidants, buffers, antimicrobial agents and/or toxicity adjusting agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use. The dry solid presentation may be prepared by filling a sterile powder aseptically into individual sterile containers or by filling a sterile solution aseptically into each container and freeze-drying.

Formulations suitable for rectal administration are preferably presented as unit-dose suppositories. These may be prepared by admixing a HM74A modulator with one or more conventional solid carriers, for example, cocoa butter or glycerides and then shaping the resulting mixture.

30

Formulations suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which may be used include vaseline, lanolin, polyethylene glycols, alcohols, and combinations of two or more thereof. The HM74A modulator is generally present at a concentration of from 0.1 to 15% w/w of the composition, for example, from 0.5 to 2%.

35

By topical administration as used herein, we include administration by insufflation and inhalation. Examples of various types of preparation for topical administration include

40

ointments, creams, lotions, powders, pessaries, sprays, aerosols, capsules or cartridges for use in an inhaler or insufflator or drops (e.g. eye or nose drops).

5 Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents and/or solvents. Such bases may thus, for example, include water and/or an oil such as liquid paraffin or a vegetable oil such as arachis oil or castor oil or a solvent such as a polyethylene glycol. Thickening agents which may be used include soft paraffin, aluminium stearate, cetostearyl alcohol, polyethylene glycols, microcrystalline wax and beeswax.

10 Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents or thickening agents.

15 Powders for external application may be formed with the aid of any suitable powder base, for example, talc, lactose or starch. Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilising agents or suspending agents.

20 Spray compositions may be formulated, for example, as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, 1,1,1,2-tetrafluoroethane, carbon dioxide or other suitable gas.

25 Capsules and cartridges for use in an inhaler or insufflator, of for example gelatin, may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

30 The pharmaceutical compositions according to the invention may also be used in combination with other therapeutic agents, for example in combination with other classes of dyslipidaemic drugs (e.g. statins, fibrates, bile-acid binding resins or nicotinic acid).

35 The compounds of the instant invention may be used in combination with one or more other therapeutic agents for example in combination with other classes of dyslipidaemic drugs e.g. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) or fibrates or bile acid binding resins or nicotinic acid. The invention thus provides, in a further aspect, the use of such a combination in the treatment of
40 diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial and the use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional

5 derivative thereof in the manufacture of a medicament for the combination therapy of disorders of lipid metabolism including dyslipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa or obesity.

10 When the compounds of the present invention are used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.

15 The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above optimally together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention. The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.

20 When combined in the same formulation it will be appreciated that the two components must be stable and compatible with each other and the other components of the formulation and may be formulated for administration. When formulated separately they may be provided in any convenient formulation, conveniently in such a manner as are known for such compounds in the art.

25 When in combination with a second therapeutic agent active against the same disease, the dose of each component may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

30 The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a physiologically acceptable salt or solvate thereof together with another therapeutically active agent.

35 The combination referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier thereof represent a further aspect of the invention.

The compounds of the formula (I) have useful duration of action.


40 The compounds of formula (I) and salts and solvates thereof may be prepared by the methodology described hereinafter, constituting a further aspect of this invention.

ABBREVIATIONS

THF	Tetrahydrofuran
TFA	Trifluoroacetic Acid
DMSO	Dimethylsulphoxide
HBTU	O-Benzotriazol-1-yl-N,N',N'-tetramethyluronium hexafluorophosphate
CDI	Carbonyl diimidazole
PyHOTs	Pyridinium tosylate

Method A

5 A process for preparing compounds of the present invention is set out in scheme (a):



Scheme (a)


wherein R represents $-Z-R^2$ as defined above.

10

Accordingly, a process according to the invention for preparing a compound of formula (I) comprises:

- 15 (i) formation of an amide between the amine group of anthranilic acid (2-amino-bezoic acid) and an activated acyl transfer reagent derived from a carboxylic acid;
- (ii) where desired or necessary converting a resultant free acid or base compound of formula (I) into a physiologically acceptable salt form or vice versa or converting
- 20 one salt form into another physiologically acceptable salt form.

A particular example of a process according to Method A is set out in scheme (a-i):




Scheme (a-i)

which comprises amide coupling of anthranilic acid with a carboxylic acid using CDI.

Method B

5 A process for preparing compounds of Formula (I) or Formula (Ia) as defined above in which Z represents $-(CH_2)_pO-$ and p is 1, is set out in scheme (b):



Scheme (b)

wherein Ar represents R^2 as defined above

- 10 a) amide bond formation by acetylation of an ester of anthranilic acid (O-protected anthranilic acid);
- b) Alkylation of aromatic alcohol with resulting methyl 2-[(chloroacetyl)amino]benzoate
- 15 c) Hydrolysis of methyl ester using lithium hydroxide (deprotection).


Accordingly, a process according to the invention for preparing a compound of formula (I) comprises:

- 20 (i) alkylation of an aromatic alcohol with methyl 2-[(chloroacetyl)amino]benzoate
- (ii) hydrolysis of methyl ester using lithium hydroxide
- (iii) where desired or necessary converting a resultant free acid or base compound of formula (I) into a physiologically acceptable salt form or vice versa or converting one salt form into another physiologically acceptable salt form.

25 The following non-limiting examples illustrate the present invention:

Synthetic ExamplesA. Example compounds synthesised using Method A

Example 1: 2-(3-Naphthalen-1-yl-propanoylamino)-benzoic acid














3-Naphthalen-1-yl-propionic acid (20 mgs, 0.1 mmol) was dissolved in acetonitrile (1 ml). HBTU (38 mgs, 0.1 mmol) was added and the mixture stirred for 30 minutes. Then, 2-amino-benzoic acid (14 mgs, 0.1 mmol) was added followed by triethylamine (0.1ml). The reaction mixture was stirred at room temperature for 20 hours before the addition of water (0.1 ml) and evaporation under reduced pressure. The title compound was isolated using preparative HPLC. δ_H (400MHz, DMSO- d_6) 2.81 (2H, t), 3.43 (2H, t), 7.16 (1H, t), 7.43 (2H, d), 7.52-7.58 (3H, m), 7.75-7.82 (1H, m), 7.92-7.98 (2H, m), 8.14 (1H, d), 8.48 (1H, d), 11.24 (1H, br.s), 13.45 (1H, br.s); m/z 318.5 [M-H⁻].

HPLC conditions used for the purification : 8 minute run time. Solvents: 0.1% TFA in MeCN and 0.1% TFA in water. MeCN increased from 10% to 95% linearly over 5 minutes. Held at 95% for 1 min. Decreased to 10% linearly over 30 seconds. Equilibrated at 10% for 1.5 minutes before next injection.

Examples 2 to 23 were prepared as set out in Example 1.

Example	Structure	LCMS [M-H ⁻]
2		321.21
3		312.16
4		310.27
5		319.19 [M+H ⁺]

6		325.68
7		347.33
8		321.21
9		308.37
10		398.14
11		335.10
12		348.07
13		324.12
14		335.32
15		339.29[M+H ⁺]
16		309.28[M+H ⁺]

17		319.36
18		323.15[M+H ⁺]
19		339.83
20		319.22
21		321.69
22		317.23
23		348.23

Example 2:

5 δ_H (400MHz, DMSO-d₆) 2.00 (2H, m), 2.45 (2H, t), 2.75 (2H, t), 6.96 (1H, t), 7.05 (1H, t), 7.11-7.15 (2H, m), 7.32 (2H, d), 7.51-7.57 (2H, m), 7.96 (1H, d), 8.50 (1H, d), 10.75 (1H, br.s), 11.20 (1H, br.s); m/z 321.21 [M-H⁺].

Example 4:

10 δ_H (400MHz, DMSO-d₆) 6.09 (2H, s), 6.75 (1H, d), 6.96 (1H, d), 7.16-7.22 (2H, m), 7.44 (1H, s), 7.58 (1H, t), 8.00 (1H, d), 8.61 (1H, d), 11.34 (1H, br.s), 13.35 (1H, br.s); m/z 310.27 [M-H⁺].

Example 5:

15 δ_H (400MHz, DMSO-d₆) 7.08 (1H, d), 7.23 (1H, t), 7.66 (1H, t), 7.82 (1H, t), 7.94 (1H, t), 8.03 (1H, d), 8.24 (1H, d), 8.29 (1H, s), 8.31 (1H, d), 8.62 (1H, d), 8.96 (1H, s), 9.40 (1H, s), 11.45 (1H, br.s); m/z 319.19 [M+H⁺].

Example 6:

δ_H (400MHz, DMSO-d₆) 1.88 (2H, m), 2.37 (2H, t), 2.56 (2H, t), 5.95 (2H, s), 6.66 (1H, d), 6.81 (2H, m), 7.13 (1H, t), 7.57 (1H, t), 7.96 (1H, d), 8.47 (1H, d), 11.10 (1H, s), 13.74 (1H, br.s); m/z 325.68 [M-H⁺].

5 Example 7:

δ_H (400MHz, DMSO-d₆) 3.98 (2H, d), 7.60 (3H, m), 7.92-8.03 (6H, m), 8.50 (1H, s), 8.97 (1H, t); m/z 347.33 [M-H⁺].

Example 10:

10 δ_H (400MHz, DMSO-d₆) 2.97 (3H, s), 4.33 (2H, s), 7.16 (1H, t), 7.60 (1H, t), 7.70 (1H, m), 7.79 (1H, t), 8.01 (1H, d), 8.34 (1H, d), 8.43 (1H, d), 8.55 (2H, t), 9.05 (1H, m); m/z 398.14 [M-H⁺].

Example 11:

15 δ_H (400MHz, DMSO-d₆) 2.34 (3H, s), 2.60 (2H, t), 3.03 (2H, t), 3.62 (3H, s), 6.94 (1H, t), 7.04 (1H, t), 7.10 (1H, t), 7.32 (1H, d), 7.48 (1H, d), 7.57 (1H, t), 7.95 (1H, d), 8.50 (1H, d), 11.15 (1H, br.s), 13.41 (1H, br.s); m/z 335.10 [M-H⁺].

Example 12:

20 δ_H (400MHz, DMSO-d₆) 2.59 (2H, t), 3.38 (2H, t), 3.91 (3H, s), 7.15 (1H, t), 7.35 (1H, t), 7.43 (1H, d), 7.50 (1H, t), 7.59 (1H, t), 7.85 (2H, m), 7.97 (1H, d), 8.02 (1H, d), 8.50 (1H, d), 11.20 (1H, br.s), 13.45 (1H, br.s); m/z 348.07 [M-H⁺].

Example 13:

25 δ_H (400MHz, DMSO-d₆) 2.86 (2H, t), 3.19 (2H, t), 7.14 (1H, t), 7.36-7.44 (2H, m), 7.49 (1H, s), 7.58 (1H, t), 7.87 (1H, d), 7.97 (2H, d), 8.48 (1H, d), 11.25 (1H, br.s), 13.55 (1H, br.s); m/z 324.12 [M-H⁺].

Example 14:

30 δ_H (400MHz, DMSO-d₆) 2.90 (2H, t), 4.27 (2H, t), 6.60 (1H, d), 7.15 (1H, t), 7.36-7.44 (2H, m), 7.48-7.52 (2H, m), 7.68 (1H, t), 7.95 (1H, d), 8.22 (1H, d), 8.41 (1H, d), 11.08 (1H, br.s); m/z 335.32 [M-H⁺].

Example 15:

35 δ_H (400MHz, DMSO-d₆) 2.91 (2H, t), 3.79 (3H, s), 4.46 (2H, t), 6.31 (1H, d), 6.65 (1H, dd), 7.07 (1H, d), 7.15 (1H, t), 7.22 (1H, d), 7.37 (1H, d), 7.58 (1H, t), 7.94 (1H, d), 8.43 (1H, d), 11.08 (1H, br.s), 13.53 (1H, br.s); m/z 339.29 [M+H⁺].

Example 16:

40 δ_H (250MHz, DMSO-d₆) 2.93 (2H, t), 4.51 (2H, t), 6.41 (1H, d), 7.01 (1H, t), 7.10-7.17 (2H, m), 7.38 (1H, d), 7.54 (3H, m), 7.94 (1H, dd), 8.40 (1H, d), 11.05 (1H, br.s), 13.52 (1H, br.s); m/z 309.28 [M+H⁺].

Example 18:

δ_H (400MHz, DMSO-d₆) 2.21 (3H, s), 2.88 (2H, t), 4.43 (2H, t), 6.99 (1H, t), 7.12 (3H, m), 7.45 (2H, m), 7.56 (1H, t), 7.94 (1H, dd), 8.40 (1H, d), 11.19 (1H, br.s); m/z 323.15 [M+H⁺].

Example 19:


δ_H (400MHz, DMSO-d₆) 1.13 (3H, t), 2.60 (4H, m), 2.90 (2H, t), 5.95 (2H, s), 6.68 (2H, m), 7.13 (1H, t), 7.58 (1H, t), 7.97 (1H, d), 8.48 (1H, d), 11.12 (1H, br.s); m/z 339.83 [M-H⁻].

Example 21:

δ_H (400MHz, DMSO-d₆) 2.36 (3H, s), 2.74 (2H, t), 3.03 (2H, t), 6.89 (1H, d), 7.08 (1H, s), 7.15 (1H, t), 7.20 (1H, d), 7.31 (1H, s), 7.59 (1H, t), 7.97 (1H, d), 8.51 (1H, d), 10.61 (1H, br.s), 11.24 (1H, br.s); m/z 321.69 [M-H⁻].


Acid intermediates for preparation of examples 2-23 are known compounds, either commercially available or synthesised by reported procedures with the exception of:

Acid for Example 10: [Methyl-(quinoline-8-sulfonyl)-amino]-acetic acid:




[Methyl-(quinoline-8-sulfonyl)-amino]-acetic acid was prepared from commercially available (quinoline-8-sulfonylamino)-acetic acid by methylation using excess methyl iodide in DMF and subsequent hydrolysis of the methyl ester using a methanolic solution of 2N sodium hydroxide (1:1 mixture).


Acid for Example 21: 3-Isoquinolin-4-yl-propionic acid



3-Isoquinolin-4-yl-propionic acid prepared from the known compound 3-Isoquinolin-4-yl-propionic acid *tert*-butyl ester (Jonczyk *et al*, J. Chem. Res. Synop., 1998, (5), 262-3) by deprotection under standard conditions (20% TFA in DCM for 4 hours).

Example 24: 2-[[3-(2-naphthalenyl)propanoyl]amino]benzoic acid


3-(2-naphthalenyl)propanoic acid (150mg, 0.75mmol, 1equiv) and 1,1-carbonyldiimidazole (146mg, 0.9mmol, 1.2equiv) were stirred vigorously in anhydrous THF (4ml) under nitrogen. After 1 hour, anthranilic acid (161mg, 1.17mmol, 1.3equiv) and pyridinium p-toluene sulfonate (543mg, 2.16mmol, 2.4equiv) were added and the mixture was refluxed under nitrogen. After 18 hours the mixture was cooled to room temperature before being filtered through Celite and evaporated under reduced pressure. Purification by SPE (C18, 20g) eluting 3-95% MeCN: water, afforded the title compound as a white solid (80mg, 33%); δ_H (400 MHz, d_6 -DMSO) 2.83 (2H, t, $J=7.5\text{Hz}$), 3.12 (2H, t, $J=7.5\text{Hz}$), 7.13 (1H, app t, $J=7.5\text{Hz}$), 7.43-7.49 (3H, m), 7.57 (1H, app t, $J=8.0\text{Hz}$), 7.76 (1H, br s), 7.82-7.87 (3H, m), 7.96 (1H, dd, $J=8.0$ and 1.6Hz), 8.48 (1H, d, $J=8.5\text{Hz}$), 11.18 (1H, s), 13.61 (1H, br s); m/z 320.2 $[MH^+]$.

Example 25: 2-[[3-(1,2,3,4-tetrahydro-1-naphthalenyl)propanoyl]amino]benzoic acid

Prepared as for Example 24 using 3-(1,2,3,4-tetrahydro-1-naphthalenyl)propanoic acid (100mg, 0.49mmol, 1equiv) and anthranilic acid (88mg, 0.64mmol, 1.3equiv). Purification by SPE (C18, 5 g) eluting 3-95% MeCN: water, afforded the title compound as a tan oil (45mg, 28%); δ_H (400 MHz, $DMSO-d_6$) 1.60-1.72 (2H, m), 1.73-1.89 (3H, m), 2.00-2.10 (1H, m), 2.40-2.52 (2H, m), 2.65-2.85 (3H, m), 7.00-7.18 (4H, m), 7.21 (1H, d, $J=7.5\text{Hz}$), 7.57 (1H, t, $J=8.0\text{Hz}$), 7.97 (1H, d, $J=8.0\text{Hz}$), 8.48 (1H, d, $J=8.0\text{Hz}$), 11.18 (1H, s), 13.60 (1H, v br s); m/z 324.2 $[MH^+]$.


B. Example compounds synthesised using Method B

A generalised method for carrying out Method B is as follows:






Polystyrene-supported 1,5,7-triazabicyclo[4.4.0]dec-5-ene [Fluka AG, crosslinked with 2% 1,4-divinylbenzene, loading 2.6 mmol/g] is treated with a solution of Ar-OH in acetonitrile. After 1 hour the mixture is treated with a solution of methyl 2-[(chloroacetyl)amino]benzoate (Journal of Heterocyclic Chemistry 1989, 26(6), 1807-1810) in acetonitrile and then heated at around 45°C for around 18 hours. The cooled mixture is filtered and the residue washed with further acetonitrile. The filtrate and washings are combined, evaporated to dryness and the residue treated with a solution of lithium hydroxide in a mixture of methanol, water and THF. The mixture is stirred and heated to around 45°C for about 2 hours then stirred at ambient temperature for around 18 hours. The mixture is acidified to about pH4 by the addition of 2M aqueous hydrochloric acid and the precipitated product filtered and dried to afford the title compound.

The following compounds example 26-34 were also prepared using method A



Example No:	Compound: Ar =	Yield	m/z
26		2.8mg (5.8%)	322 [MH ⁺]
27		3.6mg(7.7%)	311 [MH ⁺]
28		3.2mg (6.6%)	323 [MH ⁺]
29		2.9mg (5.9%)	326 [MH ⁺]
30		21.6mg (42.2%)	341 [MH ⁺]

Example No:	Compound: Ar =	Yield	m/z
31		14.4mg (27%)	355 [MH ⁺]
32		20.5mg (38.4%)	356 [MH ⁺]
33		1.6mg (3%)	355 [MH ⁺]

Example 26

2-[[[(2-naphthalenyloxy)acetyl]amino]benzoic acid

5 NMR δ H (400MHz, d6-DMSO) 4.87(s, 2H), 7.20(t, 1H, J=7.8Hz), 7.35–7.41(m, 2H), 7.45–7.51(m, 2H), 7.64(dd, 1H, J=1.5, 7.0Hz), 7.83(d, 1H, J=8.3Hz), 7.87(d, 1H, J=8.0Hz), 7.92(d, 1H, J=8.8Hz), 8.03(dd, 1H, J=1.5, 7.8Hz), 8.73(d, 1H, J=8.3Hz), 12.31(s, 1H), one exchangeable proton not observed to δ H 13.

Example 27

10 2-[[[(1H-indol-5-yloxy)acetyl]amino]benzoic acid

NMR δ H (400MHz, d6-DMSO) 4.69 (s, 2H), 6.33-6.38 (m, 1H), 6.94 (dd, 1H, J=2.5, 8.6Hz), 7.17-7.20 (m, 3H), 7.31-7.34 (m, 2H), (dt, 1H, J=1.5, 7.3Hz), 8.02 (dd, 1H, J=1.5 and 7.8Hz), 8.73 (d, 1H, J=8.1Hz), 11.00 (s, 1H), 12.28 (s, 1H).

15 Example 28

2-[[[(7-quinolinyloxy)acetyl]amino]benzoic acid

20 NMR δ H (400MHz, d6-DMSO) 4.93 (s, 2H), 7.18 (t, 1H, J=7.1Hz), 7.40-7.51 (m, 3H), 7.62 (dt, 1H, J=1.5, 8.6Hz), 7.98 (d, 1H, J=8.8Hz), 8.03 (dd, 1H, J=1.5, 7.8Hz), 8.31 (dd, 1H, J=1.5, 8.3Hz), 8.71 (d, 1H, J=8.1Hz), 8.84 (dd, 1H, J=1.7, 4.3Hz), 12.46 (br s, 1H), one exchangeable proton not observed to δ H 13.

Example 29

2-[[[(5,6,7,8-tetrahydro-2-naphthalenyloxy)acetyl]amino]benzoic acid

25 NMR δ H (400MHz, d6-DMSO) 1.75-1.96 (m, 4H), 2.69-2.87 (m, 2H), 2.88-2.96 (m, 2H), 4.67 (s, 2H), 6.92-6.99 (m, 2H), 7.09-7.16 (m, 2H), 7.41 (t, 1H, J= 8.4Hz), 8.13 (d,

1H, J=8.4Hz), 8.68 (d, 1H, J=8.4Hz), both exchangeable protons not observed to δ H 13.

Example 30

5 2-({[(3-ethyl-1,2-benzisoxazol-6-yl)oxy]acetyl}amino)benzoic acid
NMR δ H (400MHz, d6-DMSO) 1.33 (t, 3H, J=7.5Hz), 2.96 (q, 2H, J=7.5Hz), 4.82 (s, 2H), 7.11 (t, 1H, J=7.5Hz), 7.17 (dd, 1H, J=1.5, 8.5Hz), 7.37 (d, 1H, J=1.8Hz), 7.49 (t, 1H, J=6.5Hz), 7.82 (d, 1H, J=8.8Hz), 8.01 (d, 1H, J=7.8Hz), 8.63 (d, 1H, J=8.5Hz), both exchangeable protons not observed to δ H 13.

Example 31

10 2-({[(3-propyl-1,2-benzisoxazol-6-yl)oxy]acetyl}amino)benzoic acid
NMR δ H (400MHz, d6-DMSO) 0.96 (t, 3H, J=7.5Hz), 1.78 (m, 2H), 2.92 (t, 2H, J=7.5Hz), 4.86 (s, 2H), 7.15-7.19 (m, 2H), 7.39 (d, 1H, J= 2.0Hz), 7.59 (t, 1H, J=8.0Hz), 7.84 (d, 1H, J=8.5Hz), 8.03 (d, 1H, J=7.8Hz), 8.68 (d, 1H, J=8.3Hz), 12.41-12.83 (br s, 1H), one exchangeable proton not observed to δ H 13.

Example 32

20 2-({[(2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)oxy]acetyl}amino)benzoic acid
NMR δ H (400MHz, d6-DMSO) 1.24 (s, 6H), 1.72 (t, 2H, J=6.5Hz), 2.71 (t, 2H, J=6.5Hz), 4.59 (s, 2H), 6.65-6.67 (m, 1H), 6.81-6.84 (m, 2H), 7.14 (t, 1H, J=7.5Hz), 7.55 (t, 1H, J=7.3Hz), 8.02 (dd, 1H, J=1.3, 7.8Hz), 8.67 (d, 1H, J=8.3Hz), 12.65-12.82 (br s, 1H), one exchangeable proton not observed to δ H 13.

Example 33


25 2-({[(1-acetyl-2,3-dihydro-1H-indol-5-yl)oxy]acetyl}amino)benzoic acid
NMR δ H (400MHz, d6-DMSO), 2.19(s, 3H), 3.19(t, 2H, J=8.3Hz), 4.10(t, 2H, J=8.3Hz), 4.59 (2, 2H), 6.90(d, 1H, J=9.1Hz), 7.04-7.11(m, 2H), 7.37(t, 1H, J=7.6Hz), 7.98-8.07(m, 2H), 8.57(d, 1H, J=8.3Hz), both exchangeable protons not observed to δ H 13.

30 All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

35 The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and
40 may include, by way of example and without limitation the following claims:

Claims

1. A compound selected from: a compound of Formula (I)



and a salt, solvate or physiologically functional derivative thereof, wherein:

R¹ represents hydrogen, halogen or C₁-C₃alkyl;

R² represents a 9 or 10-member saturated, partially saturated or unsaturated bi-cyclic ring system optionally including from 1 to 3 heteroatoms independently selected from S, O and N;

Z represents a linker unit selected from: $-(CH_2)_n-$; $-CH=CH-(CH_2)_m-$; $-(CH_2)_pNHC(O)-$; $-(CH_2)_pNHC(O)NH-$; $-(CH_2)_pNHC(O)O-$; $-(CH_2)_pSO_2NR^3-$; $-(CH_2)_pNR^3SO_2-$; $-(CH_2)_pO-$ and $-O-$;

n represents an integer selected from 2, 3 and 4;


m represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2; and

R³ represents hydrogen or C₁-C₄alkyl, with the proviso that when R¹ is H, Z is $-(CH_2)_n-$ and n = 2 or 3, R² is other than indol-3-yl.

2. A compound according to claim 1 wherein R¹ represents hydrogen, fluorine or methyl.
3. A compound according to claim 2 wherein R¹ represents hydrogen.
4. A compound according to any preceding claim wherein Z represents $-(CH_2)_pO-$ or $-(CH_2)_n-$.
5. A compound according to claim 4 wherein Z represents $-(CH_2)_n-$ and n represents an integer selected from 2, 3 or 4.
6. A compound according to claim 5 wherein Z is $-(CH_2)_n-$ and n is 2.


7. A compound according to claim 4 wherein Z represents $-(CH_2)_pO-$ and n represents 1.
8. A compound according to any preceding claim wherein R^2 is a 10-member bi-cyclic ring system.
9. A compound according to claim 8 wherein R^2 is naphthyl.
10. A compound according claim 8 wherein R^2 is a 10-member ring system having either 1 or 2 heteroatoms.
11. A compound according to claim 10 wherein R^2 includes 1 or 2 nitrogen heteroatoms.
12. A compound according to any one of claims 9, 10 or 11 wherein R^2 is selected from the group consisting of:



13. A compound according claim 8 wherein R^2 is substituted with one or more groups selected from C_1 - C_2 alkyl, $-C(O)Me$, $=O$ and C_1 - C_3 alkoxy.
14. A compound according claim 13 wherein R^2 is substituted with one or more groups selected from methyl and methoxy.
15. A compound according any one of claims 1-7 wherein R^2 is a 9-member ring system selected from the group consisting of fused aryl-cycloalkyl, fused aryl and fused heteroaryl systems.

16. A compound according to claim 15 wherein R² includes 1 to 3 heteroatoms selected from S, O or N.

17. A compound according to claim 15 or claim 16 wherein R² is selected from the group consisting of:



wherein R⁴ represents hydrogen, methyl, CO₂H or CO₂Me.

18. A compound according to claim 17 wherein R² is substituted with one or more groups selected from C₁-C₃alkyl -C(O)Me, =O, C₁-C₃alkoxy, CO₂H and CO₂Me.


19. A compound according to claim 18 wherein R² is substituted with methyl or methoxy.

20. A compound according to any preceding claim for use in human or veterinary medicine.

21. A compound according to any one of claims 1-19 for use in treating disorders of lipid metabolism including dislipidaemia and hyperlipoproteinaemia or in treating inflammatory diseases or conditions.

22. The use of a compound according to any one of claims 1-19 in the manufacture of a medicament for the treatment of disorders of lipid metabolism including dislipidaemia and hyperlipoproteinaemia or of inflammatory diseases or conditions.

23. A compound selected from: a compound of Formula (Ia)



and a salt, solvate or physiologically functional derivative thereof, wherein:

R^1 represents hydrogen, halogen or C_1 - C_3 alkyl;

R^2 represents a 9 or 10-member saturated, partially saturated or unsaturated bi-cyclic ring system optionally including from 1 to 3 heteroatoms independently selected from S, O and N;

Z represents a linker unit selected from: $-(CH_2)_n-$; $-CH=CH-(CH_2)_m-$; $-(CH_2)_pNHC(O)-$; $-(CH_2)_pNHC(O)NH-$; $-(CH_2)_pNHC(O)O-$; $-(CH_2)_pSO_2NR^3-$; $-(CH_2)_pNR^3SO_2-$; and $-O-$;

n represents an integer selected from 2, 3 and 4;

m represents an integer selected from 0, 1 and 2;


p represents an integer selected from 1 and 2; and

R^3 represents hydrogen or C_1 - C_4 alkyl,

for use in the treatment of disorders of lipid metabolism including dyslipidaemia and hyperlipoproteinaemia or of inflammatory diseases or conditions.

24. A compound according to claim 23 for use in the treatment of diabetic dyslipidaemia, mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia, coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity.

25. Use of a compound selected from: a compound of Formula (Ia)



and a salt, solvate or physiologically functional derivative thereof, wherein

R^1 represents hydrogen, halogen or C_1 - C_3 alkyl;

R^2 represents a 9 or 10-member saturated, partially saturated or unsaturated bi-cyclic ring system optionally including from 1 to 3 heteroatoms independently selected from S, O and N;

Z represents a linker unit selected from: $-(CH_2)_n-$; $-CH=CH-(CH_2)_m-$; $-(CH_2)_pNHC(O)-$; $-(CH_2)_pNHC(O)NH-$; $-(CH_2)_pNHC(O)O-$; $-(CH_2)_pSO_2NR^3-$; $-(CH_2)_pNR^3SO_2-$; and $-O-$;

n represents an integer selected from 2, 3 and 4;

m represents an integer selected from 0, 1 and 2;


p represents an integer selected from 1 and 2; and

R^3 represents hydrogen or C_1 - C_4 alkyl,

in the manufacture of a medicament for the treatment of disorders of lipid metabolism including dyslipidaemia or hyperlipoproteinaemia or of inflammatory diseases or conditions.

26. The use of claim 25 wherein the disorder is selected from diabetic dyslipidaemia, mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia, coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa and obesity.

27. A method for the treatment of a human or animal subject having a condition where under-activation of the HM74A receptor contributes to the condition or where activation of the receptor will be beneficial, which method comprises administering to said human or animal subject an effective amount of a compound selected from a compound of Formula (Ia)



and a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, wherein

- R^1 represents hydrogen, halogen or C_1 - C_3 alkyl;

R^2 represents a 9 or 10-member saturated, partially saturated or unsaturated bi-cyclic ring system optionally including from 1 to 3 heteroatoms independently selected from S, O and N;

- Z represents a linker unit selected from: $-(CH_2)_n-$; $-CH=CH-(CH_2)_m-$; $-(CH_2)_pNHC(O)-$; $-(CH_2)_pNHC(O)NH-$; $-(CH_2)_pNHC(O)O-$; $-(CH_2)_pSO_2NR^3-$; $-(CH_2)_pNR^3SO_2-$; and $-O-$;


- n represents an integer selected from 2, 3 and 4;

m represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2; and

- R^3 represents hydrogen or C_1 - C_4 alkyl.

28. A method for the treatment of a human or animal subject having a disorder of lipid metabolism including dislipidaemia or hyperlipoproteinaemia or having an inflammatory disease or condition, which method comprises administering to said human or animal subject an effective amount of a compound selected from a compound of Formula (Ia)



and a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, wherein

5 R^1 represents hydrogen, halogen or C_1 - C_3 alkyl;

R^2 represents a 9 or 10-member saturated, partially saturated or unsaturated bi-cyclic ring system optionally including from 1 to 3 heteroatoms independently selected from S, O and N;

10

Z represents a linker unit selected from: $-(CH_2)_n-$; $-CH=CH-(CH_2)_m-$; $-(CH_2)_pNHC(O)-$; $-(CH_2)_pNHC(O)NH-$; $-(CH_2)_pNHC(O)O-$; $-(CH_2)_pSO_2NR^3-$; $-(CH_2)_pNR^3SO_2-$; and $-O-$;

15

n represents an integer selected from 2, 3 and 4;

m represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2; and

20

R^3 represents hydrogen or C_1 - C_4 alkyl.

25 29. A pharmaceutical formulation comprising a compound according to any one of claims 1-19 in admixture with one or more physiologically acceptable diluents, excipients or carriers.

30 30. A combination for administration together or separately, sequentially or simultaneously in separate or combined pharmaceutical formulations, said combination comprising a compound according to any one of claims 1-19 together with another therapeutically active agent.

35 31. A pharmaceutical formulation comprising a compound according to any one of claims 1-19, a further active ingredient selected from the group consisting of statins, fibrates, bile-acid binding resins and nicotinic acid and one or more physiologically acceptable diluents, excipients or carriers.

32. A process for the preparation of a compound according to any one of claims 1-19, the method comprising the steps of:

- 5 i. alkylation of an aromatic alcohol with methyl 2-[(chloroacetyl)amino]benzoate
- ii. hydrolysis of methyl ester using lithium hydroxide
- iii. where desired or necessary converting a resultant free acid or base compound of formula (I) into a physiologically acceptable salt form or vice versa or converting one salt form into another physiologically acceptable salt form.

10

33. A process for the preparation of a compound according to any one of claims 1-19, the method comprising the steps of:

- 15 i. formation of an amide between the amine group of anthranilic acid (2-amino-bezoic acid) and an activated acyl transfer reagent derived from a carboxylic acid;
- ii. where desired or necessary converting a resultant free acid or base compound of formula (I) into a physiologically acceptable salt form or vice versa or converting one salt form into another physiologically acceptable salt form.

20

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 February 2005 (24.02.2005)

PCT

(10) International Publication Number
WO 2005/016867 A3

(51) International Patent Classification⁷: **C07C 233/55**,
C07D 209/18, 317/60, 217/14, C07C 237/22, C07D
215/36, C07C 235/38, C07D 333/60, C07C 235/24, A61K
31/196, 31/33

Essex CM19 5AW (GB). SMITH, Ian, Edward, David
[GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage
Hertfordshire SG1 2NY (GB).

(21) International Application Number:
PCT/GB2004/003516

(74) Agent: THORNLEY, Rachel, Mary; GlaxoSmithKline,
Corporate Intellectual Property (CN925.1), 980 Great West
Road, Brentford Middlesex TW8 9GS (GB).

(22) International Filing Date: 13 August 2004 (13.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0319126.9 14 August 2003 (14.08.2003) GB

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, PO Box 7929, Philadelphia,
Pennsylvania 19101 (US).

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CAMPBELL,
Mathew [GB/GB]; GlaxoSmithKline, Gunnels Wood
Road, Stevenage Hertfordshire SG1 2NY (GB). HAT-
LEY, Richard, Jonathan [GB/GB]; GlaxoSmithKline,
Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY
(GB). HEER, Jag, Paul [GB/GB]; GlaxoSmithKline,
New Frontiers Science Park South, Third Avenue, Harlow
Essex CM19 5AW (GB). MASON, Andrew, McMur-
trie [GB/GB]; GlaxoSmithKline, Gunnels Wood Road,
Stevenage Hertfordshire SG1 2NY (GB). PINTO, Ivan,
Leo [GB/GB]; GlaxoSmithKline, Gunnels Wood Road,
Stevenage Hertfordshire SG1 2NY (GB). RAHMAN,
Shahzad, Sharooq [GB/GB]; GlaxoSmithKline, New
Frontiers Science Park South, Third Avenue, Harlow


Published:

— with international search report

(88) Date of publication of the international search report:
31 March 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ANTHRANILIC ACID DERIVATIVES AND THEIR USE AS ACTIVATORS OF THE HM74A RECEPTOR



(57) Abstract: Therapeutically active anthranilic acid derivatives of Formula (I) wherein R¹, R² and Z are as defined in the speci-
fication, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compounds and the use
of the compounds in therapy, particularly in the treatment of diseases in which under-activation of the HM74A receptor contributes
to the disease or in which activation of the receptor will be beneficial, are disclosed.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/003516

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C233/55 C07D209/18 C07D317/60 C07D217/14 C07C237/22
C07D215/36 C07C235/38 C07D333/60 C07C235/24 A61K31/196
A61K31/33

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, CHEM ABS Data, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98/34909 A1 (CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D.) 13 August 1998 (1998-08-13) claims 3-7; examples 13,14 page 12, line 41 - page 13, line 5	1-3,8, 13,14, 20,21, 23,24, 29,30,33
X	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; OGANESYAN, EDUARD TONIKOVICH ET AL: "Derivatives of 6-methoxychromonyl-3-acrylanilide showing antiallergic activity" XP002311348 retrieved from STN Database accession no. 1997:53544 abstract -/--	1-3,8, 10,13, 20,21, 23,24,29

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

20 December 2004

Date of mailing of the international search report

04/01/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Seufert, G

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/003516

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>& RU 2 051 914 C1 (PYATIGORSKII FARMATSEVTICHESKII INSTITUT, TAJIKISTAN) 10 January 1996 (1996-01-10)</p> <p>-----</p> <p>DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; EJIRI, KATSUJI ET AL: "Preparation of 3,4-dihydro-2H-benzopyran derivatives as allergy inhibitors and their pharmaceutical compositions" XP002311349 retrieved from STN Database accession no. 1988:94385 abstract & JP 62 132879 A2 (KURARAY CO., LTD., JAPAN) 16 June 1987 (1987-06-16)</p> <p>-----</p>	<p>1-3,8, 10,13, 14,20, 21,23, 24,29,33</p>
X	<p>DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MATSUO, KYOKO ET AL: "Preparation of 3,4-dihydro-2H-benzopyrans and their use as pharmaceuticals" XP002311350 retrieved from STN Database accession no. 1991:81586 abstract & JP 02 215778 A2 (KURARAY CO., LTD., JAPAN; YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.) 28 August 1990 (1990-08-28)</p> <p>-----</p>	<p>1-3,8, 10,13, 14,20, 21,23, 24,29,33</p>
X	<p>DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FUJISAWA, SHINICHI ET AL: "Preparation and formulation of chromone derivatives as allergy inhibitors" XP002311351 retrieved from STN Database accession no. 1991:122061 abstract & JP 02 255672 A2 (TSUMURA AND CO., JAPAN) 16 October 1990 (1990-10-16)</p> <p>-----</p>	<p>1-4,7,8, 10,13, 14,20, 21,23, 24,29,32</p>
X	<p>DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; OGANESYAN, E. T. ET AL: "Synthesis and antiallergic activity of 3-(3-chromonyl)acrylic acid derivatives" XP002311352 retrieved from STN Database accession no. 1996:26942 abstract</p> <p>-----</p>	<p>1-3,8, 10,13, 14,20, 21,23, 24,29,33</p>

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/003516

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>& KHIMIKO-FARMATSEVTICHESKII ZHURNAL , 29(10), 22-4 CODEN: KHFZAN; ISSN: 0023-1134, 1995,</p> <p>-----</p> <p>DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HASHIMOTO, KINJI ET AL: "Naphthalene derivatives" XP002311353 retrieved from STN Database accession no. 1986:33908 abstract & JP 60 139646 A2 (OTSUKA PHARMACEUTICAL FACTORY, INC., JAPAN) 24 July 1985 (1985-07-24)</p> <p>-----</p>	<p>1-3,8,9, 13,14, 20,21, 23,24,29</p>
X	<p>DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TSUCHIYA, NAOKI ET AL BENZOIC ACID, 2-''3--1-OXO-2- PROPENYL!AMINO!- (9CI): "Preparation of anthranilic acid derivatives as preventive or therapeutic agents" XP002311354 retrieved from STN Database accession no. 2000:84754 abstract & WO 00/05198 A1 (TEIJIN LIMITED, JAPAN) 3 February 2000 (2000-02-03)</p> <p>-----</p>	<p>1-4,8,9, 20,21, 23,24,29</p>
X	<p>DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002311355 Database accession no. BRN 352950 abstract & NARANG ET AL.: J. INDIAN CHEM. SOC., 13, 1936, page 260, 262,</p> <p>-----</p>	<p>1-6, 15-17</p>
X	<p>DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002311356 Database accession no. BRN 3431044 abstract & LIPOWITSCH: ZH. OBSHCH. KHIM., 23, 1953, page 811, 813,</p> <p>-----</p>	<p>1-3,8</p>

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/003516

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TUNARU, SORIN ET AL: "PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti- lipolytic effect" XP002311357 retrieved from STN Database accession no. 2003:155314 cited in the application abstract & NATURE MEDICINE (NEW YORK, NY, UNITED STATES) , 9(3), 352-355 CODEN: NAMEFI; ISSN: 1078-8956, 2003,</p>	1-33
A	<p>WO 02/084298 A (PIKE NICHOLAS BRIAN ; WISE ALAN (GB); GLAXO GROUP LTD (GB); FOORD STEV) 24 October 2002 (2002-10-24) cited in the application the whole document</p>	1-33
A	<p>US 3 855 285 A (HOLLAND G) 17 December 1974 (1974-12-17) column 1, line 6 - line 37 table in column 19, compounds 39 and 40</p>	1-33
P,X	<p>DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XU, SHIPING ET AL: "Preparation of coumarincaboxamides as TGF-.beta. inhibitors" XP002311358 retrieved from STN Database accession no. 2004:490719 abstract & WO 2004/050082 A1 (INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES, PEOP) 17 June 2004 (2004-06-17)</p>	1-4,7,8, 10,13, 14,20, 21,23, 24, 29-31,33

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2004/003516

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 27 and 28 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/003516

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9834909	A1	13-08-1998	FR 2759368 A1 AU 718198 B2 AU 6626598 A CA 2253221 A1 EP 0901462 A1 JP 11507960 T US 6326510 B1	14-08-1998 06-04-2000 26-08-1998 13-08-1998 17-03-1999 13-07-1999 04-12-2001
RU 2051914	C1	10-01-1996	NONE	
JP 62132879	A2	16-06-1987	JP 1874464 C JP 5088229 B JP 62132879 A	26-09-1994 21-12-1993 16-06-1987
JP 2215778	A2	28-08-1990	JP 2215778 A	28-08-1990
JP 2255672	A2	16-10-1990	JP 2255672 A	16-10-1990
JP 60139646	A2	24-07-1985	JP 1651663 C JP 3014296 B JP 60139646 A	30-03-1992 26-02-1991 24-07-1985
WO 0005198	A1	03-02-2000	AT 278661 T AU 750670 B2 AU 4800499 A CA 2337098 A1 CN 1319086 T DE 69920923 D1 EP 1101755 A1 US 2003232811 A1 US 6649656 B1	15-10-2004 25-07-2002 14-02-2000 03-02-2000 24-10-2001 11-11-2004 23-05-2001 18-12-2003 18-11-2003
WO 02084298	A	24-10-2002	EP 1377834 A2 WO 02084298 A2	07-01-2004 24-10-2002
US 3855285	A	17-12-1974	US 3856951 A	24-12-1974
WO 2004050082	A1	17-06-2004	NONE	